GROWING PORTFOLIO OF PROPRIETARY AND PARTNERED PROGRAMS
R&D Pipeline
Fueled by our proprietary streaMLine™ drug discovery platform and deep expertise in peptide therapeutics, Gubra is advancing a growing and diversified pipeline of proprietary and partnered drug candidates across multiple therapeutic areas.
GUBRA’S DRUG DISCOVERY & DEVELOPMENT PLATFORM
From peptide discovery to clinical proof of concept
| Title | Hover text |
|---|---|
| Target biology | Early drug discovery starts with target identification and validation. We build the disease-biology case before a single molecule is made. |
| Peptide discovery streaMLine™ |
To sharpen the drug discovery process we use our AI drug discovery technology for peptide therapeutics, StreaMLine™ to combine hit identification with machine-learning-guided optimization. |
| Pharmaceutical development |
Formulation turns a promising peptide drug into one patients can live with. We shape drug candidates for long-acting, patient-friendly dosing early in the drug development process. |
| In vitro In vivo pharmacology |
Translational medicine connects lab and clinic. Our in-house disease models test whether a candidate’s effect is likely to hold in people. |
| Preclinical development & IND-enabling activities |
This is the gate between research and clinical drug development: the evidence regulators need before a drug candidate can be tested in people. |
| CMC and drug supply |
Every new drug development programme depends on reliable supply. We make sure material is ready, at the right quality, for each step towards the clinic. |
| Clinical development to clinical PoC |
Our own clinical development programmes move through the phases of drug development. This is clinical research and development in practice: testing whether a molecule works in patients. |
| Partnering | Partners can join at any R&D stage: through research collaborations, where we discover candidates against their targets, or licence agreements, where they take a Gubra programme forward. |
Meet the Biotech leadership
Louise S. Dalbøge
Chief Science Officer
Read bio
Louise S. Dalbøge, Ph.D., Chief Science Officer Louise leads Gubra’s scientific strategy and discovery activities, bringing more than 15 years of experience in peptide drug discovery with a focus on obesity and metabolic diseases. Louise has played a central role in shaping Gubra’s pipeline and in applying machine learning to peptide discovery through the streaMLine™ platform. Louise holds an M.Sc. in Pharmacy and a Ph.D. in Endocrinology, Diabetes and Metabolism from the University of Copenhagen.
Thomas Langenickel
Chief Medical and Development Officer
Read bio
Thomas Langenickel, M.D., Chief Medical and Development Officer Thomas leads Gubra’s preclinical and clinical development strategy, bringing more than 20 years of experience in translational medicine and clinical development across therapeutic areas and modalities. He previously served as Chief Medical Officer at Ethris and held senior roles at Novartis and Bristol Myers Squibb. Thomas holds an M.D. from Humboldt University of Berlin, Germany and completed a postdoctoral fellowship in vascular biology at the NIH’s National Heart, Lung, and Blood Institute, Bethesda, USA.
Our scientific expertise, combined with AI-driven platforms, is the foundation of our strong pipeline.”
Louise S. Dalbøge
Chief Science Officer
Key figures from Biotech
10+
Alliances built through
the years
6
Active partnerships
4
Programs in clinical
development
Gubra’s lead proprietary program
WHOLLY OWNED
GUB-UCN2
| The molecule | A long-acting, highly selective CRHR2 agonist designed for once-weekly dosing. |
|---|---|
| The mechanism | It acts directly on CRHR2 receptors in skeletal muscle, driving fat loss while building and preserving muscle. |
| The data | In preclinical studies it reduced fat mass while increasing muscle mass, and it prevented muscle loss when given alongside a GLP-1 drug. |
| Where it is now | A Phase 1/2a trial in around 188 participants began in July 2026, with first data expected in the first half of 2027. |
Obesity
Beyond weight loss:
Targeting healthier body composition
Current obesity treatments deliver substantial weight loss, but reductions in body weight also include lean mass, including skeletal muscle.
GUB-UCN2 takes a differentiated approach by targeting both skeletal muscle and adipose tissue through selective CRHR2 activation, with preclinical data demonstrating reductions in fat mass while preserving or increasing skeletal muscle mass.
This supports its potential as both a standalone therapy and in combination with existing and emerging obesity treatments, with broader opportunities in muscle-related conditions, such as sarcopenia.
How we partner
Partnerships
Gubra has established partnerships with leading global pharmaceutical and biotech companies, leveraging our proprietary streaMLine™ platform and deep expertise in peptide drug discovery and development.
Our collaborations range from joint discovery and development of innovative therapeutics to licensing
Gubra-discovered drug candidates for further clinical development and commercialization.
Obesity
Amylin analog*
ABBV-295 is licensed to AbbVie from Gubra. AbbVie is solely responsible for further development and commercialization.
| The molecule | A differentiated long-acting amylin analog discovered using Gubra’s streaMLine™ platform. |
|---|---|
| The mechanism | ABBV-295 activates amylin and calcitonin receptors to promote satiety and reduce food intake through a mechanism distinct from incretin-based therapies such as GLP-1 and GIP receptor agonists. |
| The data | A comprehensive Phase 1 program has demonstrated encouraging weight loss results and a favorable safety and tolerability profile. Data from a 12/13-week Phase 1 multiple ascending dose study showed up to ~10% weight loss after 12 weeks of once-weekly dosing (vs. 0.3% for placebo), with comparable weight loss observed with every-two-week and monthly dosing after week 5, supporting the potential for less frequent dosing. These results were achieved in a predominantly male population (88%) with a mean baseline BMI below 30 kg/m2. |
| Where it is now | A Phase 2 trial in adults with overweight and obesity was initiated in August 2026. |
Obesity
triple agonist*
BI 3034701 was developed in cooperation with Boehringer Ingelheim. Boehringer Ingelheim is solely responsible for its further development and global commercialization.
| The molecule | A potential first-in-class triple GLP-1/GIP/NPY2 receptor agonist. |
|---|---|
| The mechanism | Designed to activate the GLP-1, GIP, and NPY2 receptors. The NPY2-driven central control of hunger and food intake is complemented by GLP-1/GIP-mediated appetite suppression, weight reduction, and metabolic regulation. |
| The data | Phase 1 demonstrated favorable safety and tolerability, and encouraging weight loss results. |
| Where it is now | A Phase 2 trial in adults with overweight and obesity was initiated in July 2026. |
Heavy menstrual bleeding
plasmin inhibitor*
HMB-003 was discovered under the collaboration agreement between Hemab and Gubra. HMB-003 is proprietary to Hemab, and Hemab is solely responsible for its development and commercialization.
| The molecule | A differentiated peptide-based long-acting plasmin inhibitor discovered using Gubra’s streaMLine™ platform. |
|---|---|
| The mechanism | HMB-003 directly inhibits plasmin at its active site, providing antifibrinolytic activity independent of the plasminogen activation pathway. Plasmin is a proven therapeutic target in coagulation medicine and central to bleeding in several conditions. |
| The data | Preclinical data have demonstrated a long half-life and inhibition of fibrinolysis. HMB-003 has potential as a novel antifibrinolytic treatment across multiple bleeding conditions, including heavy menstrual bleeding. |
| Where it is now | A Phase 1 study in healthy adult volunteers was initiated in September 2026. |
PBH and other rare diseases
GLP-1R antagonist*
AMX0318 is licensed to Amylyx from Gubra. Amylyx is responsible for development and commercialization of AMX0318.
| The molecule | A long-acting GLP-1 receptor antagonist discovered using Gubra’s streaMLine™ platform. |
|---|---|
| The mechanism | AMX0318 is hypothesized to reduce inappropriate insulin secretion and stabilize glucose levels by binding to the GLP-1 receptor to inhibit the exaggerated GLP-1-driven insulin response, with potential applications in post-bariatric hypoglycemia and other conditions. |
| The data | Preclinical data have demonstrated strong in vitro potency, in vivo efficacy, tolerability and a long half-life. |
| Where it is now | IND-enabling studies initiated in 2026 with an IND targeted for 2027. |
Hypoparathyroidism
Camurus*
The PTH analog is licensed to Camurus from Gubra. Camurus will develop and commercialize the product and Gubra has the option to co-finance the product through development.
| The molecule | A differentiated PTH analog discovered using Gubra’s streaMLine™ platform. |
|---|---|
| The mechanism | A PTH analog combined with Camurus’ FluidCrystal® technology to develop a long-acting therapeutic option for treatment of hypoparathyroidism. |
| Where it is now | Development candidate selected in Q2 2026, with the program progressing toward IND-enabling studies. |
Undisclosed
NPY2R agonist*
BI 1820237 was developed in cooperation with Boehringer Ingelheim. Boehringer Ingelheim is solely responsible for its further development and global commercialization.
| The molecule | A long-acting NPY2 receptor agonist. |
|---|---|
| The mechanism | Activates NPY2 receptors involved in regulating hunger and satiety, helping to reduce food intake through central appetite-control pathways. |
| The data | A Phase 1 clinical trial showed no unexpected safety concerns, and positive effects on energy intake and gastric emptying. |
| Where it is now | In 2024, Boehringer Ingelheim discontinued its development for obesity. Potential opportunities outside the obesity indication are now being explored by Boehringer Ingelheim. |
*Investigational development candidates that have not received a marketing authorization in any country worldwide.
EVENTS CALENDAR
Meet us here
Drug Discovery Chemistry Europe 2026
Gubra will attend Drug Discovery Chemistry Europe 2026 on November 10–12, 2026 in Barcelona, Spain.
Drug Discovery Chemistry Europe is organised by Cambridge Healthtech Institute (CHI) and takes place at the InterContinental Barcelona. The programme covers lead generation, AI and machine learning in drug discovery, next-generation protein degraders and protein-protein interactions, including small molecules and peptides that target them.
CBMR Innovation Summit on Cardiometabolic Health in Copenhagen
Gubra is attending the CBMR innovation Summit and Markus Rohrwild, CEO of Gubra will speak Nov 12th on “From discovery to differentiated medicines: Gubra’s unique business model for continuous innovation.
The summit is hosted by the Novo Nordisk Foundation Center for Basic Metabolic Research at the University of Copenhagen, at Comwell Copenhagen Portside in Nordhavn. Over three days, leaders from academia, biotech, pharma and healthcare meet for keynotes, talks and panel debates on the next generation of prevention and treatment for cardiometabolic disease.
Gubra Investor R&D Event 2026
A deep dive into Gubra’s differentiated innovation model, pipeline, and 2030 strategy.
October 27, 2026 · 1.00–5.00 pm GMT · London (2 Stonecutter Street) or via Webcast.
For further information